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Background: Currently, the TNM classification of malignant tumours based on clinicopathological staging remains
the standard for colorectal cancer (CRC) prognostication. Recently, we identified the mitochondrial oxidative
phosphorylation chain as a consistently overrepresented category in the published gene expression profiling (GEP)
studies on CRC prognosis.
Methods: We evaluated associations of putative regulatory single nucleotide polymorphisms (SNPs) in genes from
the oxidative phosphorylation chain with survival and disease prognosis in 613 CRC patients from Northern
Germany (PopGen cohort).
Results: Two SNPs in the 3′ untranslated region of UQCRB (complex III), rs7836698 and rs10504961, were associated
with overall survival (HR = 0.52, 95% CI 0.32–0.85 and HR= 0.64, 95% CI 0.42–0.99, for TT carriers). These associations
were restricted to the group of patients with cancer located in the colon (HR = 0.42, 95% CI 0.22–0.82 and HR= 0.46,
95% CI 0.25–0.83). Multivariate analysis indicated that both markers might act as independent prognostic markers.
Additionally, the TT carriers were ~2 times more likely to develop tumours in the colon than in the rectum. Two
SNPs in COX6B1 (complex IV) were associated with lymph node metastasis in a dominant model (rs6510502,
OR = 1.75, 95% CI 1.20–2.57; rs10420252, OR = 1.68, 95% CI 1.11–2.53); rs6510502 was associated also with distant
metastasis (OR = 1.67, 95% CI 1.09–2.56 in a dominant model).
Conclusions: This is the first report suggesting that markers in genes from the mitochondrial oxidative chain might
be prognostic factors for CRC. Additional studies replicating the presented findings are needed.Background
Colorectal cancer (CRC) is the third most common cancer
and the fourth-leading cause of cancer death worldwide
[1]. Currently, the TNM classification of malignant
tumours based on clinicopathological staging remains the
standard for CRC prognostication [2]. Many gene expres-
sion profiling (GEP) studies on prognosis of CRC have
been performed in the last decade using microarray* Correspondence: a.foersti@dkfz.de
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reproduction in any medium, provided the ortechnology, with the aim to identify a gene expression
profile to discriminate more aggressive from less aggres-
sive CRC. However, due to their low overlap in the identi-
fied genes, no reliable signature useful in the clinical
practice has been found. Recently, we published a system-
atic pathway-based enrichment analysis of 23 independent
GEP studies on prognosis of CRC [3]. This analysis indi-
cated the mitochondrial oxidative phosphorylation
(OXPHOS) chain as a significantly and consistently over-
represented prognostic category for CRC.
Already several decades ago, it was suggested that
impaired oxidative metabolism may cause malignant
growth [4]. In cancer cells, there is an enhanced glucose
use, slowing the rate of the tricarboxylic acid cycle andLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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http://www.biomedcentral.com/1471-2350/13/31oxidative phosphorylation and increasing glycolysis, as
the way to generate energy in form of adenosine triphos-
phate (ATP), despite aerobic conditions [5]. This as-
sumption, known as Warburg’s hypothesis, has been
rediscovered by a broad range of experimental
approaches showing interaction of mitochondrial metab-
olism and tumour growth [6-8]. Additionally, germline
mutations in the mitochondrial succinate dehydrogenase
(complex II of the OXPHOS chain) subunits SDHD,
SDHC, and SDHB are a frequent cause of paraganglio-
mas of the head and neck and of phaeochromocytomas
[9].
Thus, the OXPHOS chain appears as a promising can-
didate pathway for CRC progression. The OXPHOS sys-
tem, whose proteins are encoded by both nuclear and
mitochondrial DNA (mtDNA), consists of five major
protein complexes named complex I, II, III, IV, and V,
localized on the inner mitochondrial membrane. Its
main function is the generation of ATP [10]. We there-
fore selected putatively functional single nucleotide poly-
morphisms (SNPs) in the genes from the pathway, and
investigated their possible role in the progression of




The 613 patients included in the study belonged to the
population-based PopGen project in Schleswig-Holstein
(Germany) [11]. All individuals were of German origin, i.
e. with both parents born in Germany. Patients fulfilling
either the clinical Amsterdam or Bethesda criteria for
hereditary non-polyposis colorectal cancer (HNPCC)
were excluded from the study, as were patients with a
history of malignant disease or inflammatory bowel dis-
ease. For a full description of the characteristics of the
613 patients see Table 1 and Castro et al. [12]. The work
has been approved by the corresponding ethical commit-
tees and subjects gave informed consent to the work.
Gene and SNP selection
Candidate genes in the OXPHOS pathway (map00190 in
the KEGG database [13]) were selected based on a re-
cently published meta-analysis of GEP studies on CRC
prognosis [3]. Three out of the seven genes reported in
two GEP studies had SNPs in the putative regulatory
regions (ATP5C1 from complex V, COX5B and COX6B1
from complex IV). Two additional genes with SNPs in pu-
tative regulatory regions, each reported in one GEP study,
were also included, namely NDUFS2 from complex I and
UQCRB from complex III. With these selection criteria,
the four complexes from the OXPHOS chain which allow
flowing of protons between the mitochondrial matrix and
the intermembrane space, resulting into energy generation
Table 1 Characteristics of the 613 CRC patients at the
time of diagnosis (Continued)
None 517 84.3
Unknown 28 4.6
a Comprises radiotherapy (n = 13), chemotherapy (n = 86), radio-chemotherapy
(n = 59), immunotherapy (n = 3), chemotherapy plus 5FU/FA (n = 68), radio-
chemotherapy plus 5FU/FA (n = 18), and other (n =3).
b Comprises radiotherapy (n = 5) and radio-chemotherapy (n = 63).
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in the genes GAPDH and HSPD1 were also selected, since
both genes might define the cellular bioenergetic activity
of the mitochondria [6].
SNPs within the set of candidate genes (Table 2 and
Additional file 1: Table S1) were selected according to the
following criteria: minor allele frequency (MAF)> 0.05 in
HapMap CEPH population (Utah residents with ancestry
from northern and western Europe - CEU), and location
in potentially regulatory gene regions (5′ and 3′-UTR,
promoter or non-synonymous coding SNPs). In regions
with several SNPs in high linkage disequilibrium (LD),
tagSNPs were selected for genotyping. LD between the
SNPs was calculated using Haploview [14]. The promoter
SNP rs2802460 in ATP5C1 was reported to regulate ex-
pression of the gene in lymphoblastoid cell lines (eSNPs)
on a genome-wide association study of global gene expres-
sion [15]. Predictions of the possible impact of amino acid
substitutions on the structure and function of the protein
were performed with PolyPhen2 [16].Table 2 SNPs evaluated in the study

















Two additional SNPs were genotyped, but showed only one allele in the 613 sampl
MAF, minor allele frequency in the 613 CRC patients investigated; NDUFS2, NADH d
reductase); UQCRB, ubiquinol-cytochrome c reductase binding protein; COX5B, cyto
polypeptide 1; ATP5C1, ATP synthase, H + transporting, mitochondrial F1 complex, g
HSPD1, heat shock 60kDa protein 1 (chaperonin).Genotyping
The 613 DNAs used in the study were extracted from per-
ipheral venous blood using the FlexiGene chemistry (Qia-
gen, Hilden, Germany) according to the manufacturer’s
protocols. From them, 272 (44.4%) samples were subjected
to genome-wide amplification using the illustra Genomi-
Phi V2 DNA Amplification Kit (GE Healthcare, Freiburg,
Germany) according to manufacturer’s instructions. Geno-
typing was performed using 5 ng of either genomic or
whole-genome amplified DNA in 384-well plate format,
using KASPar assays on demand (KBiosciences, Hoddes-
don, UK) and following the manufacturer’s protocols.
Average genotyping call rate was 98.8%. All polymorph-
isms were in Hardy-Weinberg equilibrium.
Statistical analysis
SAS software version 9.2 (SAS Institute) was used in all
analysis. Unadjusted association between the genotyped
markers and patient characteristics were evaluated by chi-
square test. Odds ratios (ORs) with 95% confidence inter-
vals (CIs) were estimated using logistic regression. Effect of
the different genotypes on CRC survival was evaluated
using Kaplan-Meier method and was compared using log-
rank testing. Analysis of different parameters for prognostic
significance was done by univariate and multivariate Cox
proportional hazard models. P values< 0.05 were consid-
ered statistically significant. Follow-up time was calculated
from the date of CRC diagnosis to the CRC specific deathajor/minor allele Location MAF
C/T Promoter T - 0.21
G/T 5′-UTR T - 0.15
C/A Coding P20T A - 0.06
C/G Coding P352A G - 0.09
A/G 3′-UTR G - 0.17
C/T 3′-UTR T - 0.42
C/T 3′-UTR T - 0.50
T/C Promoter C – 0.06
A/C Promoter C - 0.13
G/A 5′-UTR A - 0.10
G/A Promoter A - 0.12
T/C Promoter C - 0.26
T/C 3′-UTR C - 0.36
C/T Promoter T - 0.19
C/G 5′-UTR G - 0.26
C/G Promoter G - 0.33
es: rs2071038 (COX5B) and rs955 (HSPD1).
ehydrogenase (ubiquinone) Fe-S protein 2, 49kDa (NADH-coenzyme Q
chrome c oxidase subunit Vb; COX6B1, cytochrome c oxidase subunit VIb,
amma polypeptide 1; GAPDH, glyceraldehyde-3-phosphate dehydrogenase;
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last contact with the treating physician). Taking into ac-
count the possible biological effects of the selected genes/
variants on cancer progression and a possible correlation




A total of 29 SNPs were identified in the regions of interest
(5′- and 3′-UTR, promoter and non-synonymous coding
SNPs) of the seven genes NDUFS2, UQCRB, COX5B,
COX6B1, ATP5C1, GAPDH and HSPD1 (Additional file 1:
Table S1). Out of them, 18 SNPs were selected for the asso-
ciation studies, covering all gene regions with a putative
regulatory function.
Association with survival
The two polymorphisms in the 3′-UTR region of UQCRB
(complex III) showed association with CRC survival
(Table 3 and Additional file 1: Table S2). The marker
rs7836698 was statistically significantly associated with a
decreased risk of death due to CRC (HR=0.53, 95% CI
0.31–0.91 for TT), or due to any cause (HR=0.52, 95% CI
0.32–0.85). For rs10504961, only the association with
overall survival was statistically significant (HR=0.64, 95%
CI 0.42–0.99 for TT). Interestingly, for both UQCRBTable 3 Association of two polymorphisms in UQCRB (comple
SNP Genotype Cause of d
No. Deaths (%) HR(9
rs7836698All patients CC 203 54 (26.6) 1
CT 297 77 (25.9) 0.90(0
TT 106 18 (17.0) 0.53(0
rs7836698Colon CC 97 30 (30.9) 1
CT 159 38 (23.9) 0.74(0
TT 69 10 (14.5) 0.42(0
rs7836698Rectum CC 105 23 (21.9) 1
CT 137 39 (28.5) 1.13(0
TT 37 8 (21.6) 0.73(0
rs10504961All patients CC 134 34 (25.4) 1
CT 319 78 (24.4) 0.88 (0
TT 150 36 (24.0) 0.76(0
rs10504961Colon CC 64 22 (34.4) 1
CT 168 38 (22.6) 0.61(0
TT 92 18 (19.6) 0.47(0
rs10504961Rectum CC 70 12 (17.1) 1
CT 149 39 (26.2) 1.33(0
TT 58 18 (31.0) 1.41(0
HR, hazard ratio; CI, confidence interval.polymorphisms, the TT carriers were more likely to de-
velop tumours in the colon than in the rectum, with ORs
of 2.02 (95% CI 1.24–3.28) for rs7836698 (TT vs. CC) and
1.74 (95% CI 1.08–2.78) for rs10504961 (TT vs. CC).
When survival was analysed according to the cancer site,
both SNPs showed association exclusively in the group of
patients with cancer located in the colon (HR for overall
survival 0.42, 95% CI 0.22–0.82 for rs7836698 TT carriers
and 0.46, 95% CI 0.25–0.83 for rs10504961 TT carriers),
but not in the rectum (Table 3). The Kaplan-Meier sur-
vival curves representing the survival rates of the patients
according to their genotypes, as well as the P values for
the log-rank test are presented in Figure 1.
We examined also whether inclusion of other variables
associated with CRC survival affected the parameter esti-
mates for the UQCRB polymorphisms. The risk of death
for carriers of the TT genotype at rs7836698 remained
statistically significantly decreased after adjustment for
age at diagnosis and TNM stage. Among patients with
tumour located in the colon, the hazard ratios were
similar both in the uni- and multivariate analyses for
rs7836698 and rs10504961, although the statistical sig-
nificance was sometimes lost.
Association with CRC progression
Three of the 16 SNPs investigated showed an association
with one of the different components that form the UICCx III) with survival
eath: CRC Cause of death: any
5% CI) P value Deaths (%) HR(95% CI) P value
.00 69 (34.0) 1.00
.63–1.28) 0.55 95 (32.0) 0.87(0.64–1.20) 0.41
.31–0.91) 0.02 23 (21.7) 0.52(0.32–0.85) 0.01
.00 37 (38.1) 1.00
.45–1.21) 0.23 47 (29.6) 0.75(0.48–1.18) 0.21
.21–0.87) 0.02 13 (18.8) 0.42(0.22–0.82) 0.01
.00 31 (29.5) 1.00
.67–1.90) 0.65 48 (35.0) 1.03(0.65–1.63) 0.89
.32–1.71) 0.47 10 (27.0) 0.70(0.33–1.47) 0.34
.00 47 (35.1) 1.00
.58–1.33) 0.54 97 (30.4) 0.79(0.55–1.13) 0.19
.47–1.24) 0.28 42 (28.0) 0.64(0.42–0.99) 0.05
.00 27 (42.2) 1.00
.35–1.05) 0.07 48 (28.6) 0.62(0.38–1.01) 0.06
.25–0.90) 0.02 22 (23.9) 0.46(0.25–0.83) 0.01
.00 20 (28.6) 1.00
.69–2.54) 0.39 48 (32.2) 0.98(0.58–1.66) 0.95
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STRATA: rs10504961=CC rs10504961=CT rs10504961=TT
Figure 1 Kaplan-Meier estimates of CRC specific survival (months) according to UQCRB genotypes, (a) rs7836698, all CRC patients
(n = 606), log rank p value= 0.07, (b) rs7836698, all patients diagnosed with colon cancer (n = 324), log rank p value= 0.05, (c)
rs10504961, all CRC patients (n = 606), log rank p value= 0.55, and (d) rs10504961, all patients diagnosed with colon cancer (n = 324),
log rank p value = 0.06.
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COX6B1 (complex IV) showed an association with the
presence of affected lymph nodes (rs6510502, OR=1.75,
95% CI 1.20–2.57; rs10420252, OR=1.68, 95% CI 1.11–
2.53). The polymorphism rs6510502 was also associated
with distant metastasis (OR=1.67, 95% CI 1.09–2.56). The
marker rs7971637 in GAPDH was associated with tumour
stage T3/T4 (OR=1.60, 95% CI 1.11–2.30).
Discussion
In a homogeneous Northern German population of 613
CRC patients, we observed several associations of poly-
morphisms in the OXPHOS chain with survival and pro-
gression of the disease. Mainly, two SNPs in the 3′-UTR
region of UQCRB (complex III), rs7836698 and
rs10504961, were associated with survival. The two poly-
morphisms were in relatively strong linkage disequilibrium(D′= 0.98, r2 = 0.65 in the 613 samples), explaining the as-
sociation observed with the two SNPs. Added to that, the
two studied polymorphisms in COX6B1 (complex IV),
rs6510502 in the promoter and rs10420252 in the 5′-
UTR, were associated with lymph node metastasis, and
rs6510502 also with distant metastasis. The two markers
were in high LD (D′=0.97, r2 = 0.71 in the 613 samples).
Patients carrying the TT genotype for any of the two
SNPs in the UQCRB gene had an increased CRC sur-
vival. Interestingly, the association appeared to be
restricted to the group of patients with tumour located
in the colon. Multivariate analyses confirmed that the
association was independent of other variables asso-
ciated with CRC survival, indicating that both markers
might act as independent prognostic markers. In the
group of patients with tumour located in the colon the
hazard ratios remained low, even though the significance
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included. Our results may partially explain the previ-
ously reported higher familial risk for colon than for rec-
tal cancer, which was shown to decrease gradually from
proximal colon to distal colon and to rectum [17]. Also
for survival, differences have been observed between
colon and rectal cancer, with rectal cancer having some-
what better survival compared to colon cancer [18].
UQCRB is one of the ten nucleus-encoded subunits of
the complex III in the mitochondrial respiratory chain,
the ubiquinol-cytochrome c oxidoreductase. In a gen-
ome-wide analysis of pancreatic cancer with CGH (com-
parative genomic hybridization) arrays, a DNA copy
number variation was identified at the UQCRB locus,
and this gene was suggested as a potential diagnostic
marker or a therapeutic target [19]. Recently, it has been
demonstrated that UQCRB plays a crucial role in the
oxygen sensing mechanism that regulates responses to
hypoxia. Using the small molecule terpestacin to inhibit
UQCRB, tumour angiogenesis was blocked in vivo [20].
COX6B1 is one of the ten nucleus-encoded subunits of
the complex IV in the mitochondrial respiratory chain,
the cytochrome c oxidase. Mutations in this gene have
been linked to severe infantile encephalomyopathy, a
phenotype associated with cytochrome c oxidase defi-
ciency [21]. Our results suggest that genetic variation in
the regulatory regions of genes in the OXPHOS chain
may associate with CRC progression. Whether such vari-
ation affects the gene expression pattern, impairs the
function of mitochondria and leads to cancer develop-
ment and progression remains to be elucidated.
One of the polymorphisms we investigated, rs2802460,
located on the promoter of ATP5C1 (complex V), was
reported to regulate expression of the gene in lympho-
blastoid cell lines in a genome-wide association study of
global gene expression [15]. However, this SNP did not
show any association with CRC survival or disease pro-
gression. A recent report has evaluated the role of 376
tagSNPs (one included in our study, rs11576415 in
NDUFS2) in 78 nuclear-encoded mitochondrial genes
(including ATP5C1, NDUFS2, and UQCR) in prostate
cancer risk, without clear evidence of association [22].
Another recent large association study included variants
from 90 genes involved in oxidative phosphorylation (in-
cluding ATP5C1, COX5B, COX6B1, GAPDH, and
NDUFS2) and tested their association with epithelial
ovarian cancer risk; no indication of association was
found [23]. To our knowledge, this is the first associ-
ation study of variants in the respiratory chain with CRC
survival and progression.
Conclusions
Our findings suggest a possible influence of genes in the
OXPHOS chain in CRC survival and progression, andsupport the newly discovered Warburg’s hypothesis. This
is the first report of a possible role of genes in the re-
spiratory chain in the prognosis of CRC patients, but
further independent studies are clearly needed to eluci-
date the validity of the results.
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